Skip to main content
C

Chunghwa Chemical Synthesis & Biotech Co., Ltd. — Investor Relations & Filings

Ticker · 1762 TW Manufacturing
Open in API
Filings indexed 1,573 across all filing types
Latest filing 2026-03-31 Fund Information / Fact…
Country TW Taiwan
Listing TW 1762

About Chunghwa Chemical Synthesis & Biotech Co., Ltd.

https://www.ccsb.com.tw

Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB) is a specialized manufacturer of Active Pharmaceutical Ingredients (APIs) with a history dating back to 1964. The company focuses on the research, development, and large-scale production of high-quality APIs, particularly in the therapeutic areas of oncology, antifungal treatments, and immunosuppressants. CCSB offers a broad service portfolio that includes cGMP-compliant contract manufacturing and toll manufacturing. By leveraging advanced chemical synthesis and biotechnology platforms, the company provides tailored solutions to global pharmaceutical partners. CCSB adheres to rigorous international quality standards and environmental, health, and safety protocols, ensuring the reliable supply of critical medicinal components for the global healthcare market.

Recent filings

Filing Released Lang Actions
114年度財務比率
Fund Information / Factsheet Classification · 1% confidence The document is a concise three-year financial ratio analysis table provided by the company (中化生) on Taiwan’s public disclosure platform (公開資訊觀測站). It is a brief summary (approx. 1,000 characters) of key financial metrics (liquidity, profitability, turnover ratios, etc.) rather than a full annual or interim report, management discussion, or announcement. This type of summary fits the Fund Information / Factsheet category.
2026-03-31 Chinese
114年第4季海外子公司投資
Interim / Quarterly Report Classification · 1% confidence The document is a financial table extracted from the '公開資訊觀測站' (Market Observation Post System) in Taiwan. It details specific investment data (subsidiary holdings, investment amounts, and recognized profit/loss) for the 4th quarter of the 114th year (Republic of China calendar). Since it contains substantive financial data and analysis regarding investments rather than just an announcement of a report or a certification, it qualifies as an Interim/Quarterly Report (IR) component. Q4 2025
2026-03-31 Chinese
114年度應收帳款周轉率
Financial Supplement Data Classification · 1% confidence The document contains only a brief table of two years’ receivables turnover ratio and average collection days, with no narrative, headings, or indications of a full report. It does not announce a report but provides raw financial data typically found in supplementary spreadsheets. It is too short to be an earnings release or IR and clearly not a meeting notice or management change. Therefore it fits the Financial Supplement Data category (XLSX).
2026-03-31 Chinese
114年度存貨週轉率
Regulatory Filings Classification · 1% confidence The excerpt is a brief regulatory disclosure of inventory turnover ratios and days sales outstanding for fiscal years (Taiwanese system) including mandatory explanations for changes over 20%. It is not an AGM material, earnings release, annual or interim report in itself, nor any other specific corporate action. This type of standalone ratio disclosure fits the fallback “Regulatory Filings” category (RNS).
2026-03-31 Chinese
114年度毛利率
Regulatory Filings Classification · 1% confidence The document is a brief regulatory disclosure from the Taiwan ‘公開資訊觀測站’ showing annual revenue, cost, gross profit data and a mandated margin‐change explanation. It is not a full annual or quarterly report, nor a proxy or presentation, but a standalone regulatory filing of key figures and commentary. It falls into the miscellaneous regulatory filings fallback category (RNS).
2026-03-31 Chinese
114年度營益分析
Interim / Quarterly Report Classification · 1% confidence The document is a structured financial data table provided by a listed company (中化生) via the Market Observation Post System (公開資訊觀測站). It contains specific quarterly and annual financial performance metrics (revenue, gross margin, operating profit margin, etc.) for the years 112, 113, and 114. Since it provides substantive financial data and analysis for multiple periods rather than just an announcement of a report, it qualifies as an Interim/Quarterly Report (IR). Q4 2025
2026-03-31 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.